Blood Neoplasia最新文献

{"title":"Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes","authors":"Francesca Guijarro ,&nbsp;Sandra Cabezas ,&nbsp;Marc Dabad ,&nbsp;Alex Bataller ,&nbsp;Cristina López ,&nbsp;Sandra Castaño-Díez ,&nbsp;Carlos Jiménez-Vicente ,&nbsp;Albert Cortés-Bullich ,&nbsp;Marta Garrote ,&nbsp;Jose R. Álamo ,&nbsp;Miriam Prieto ,&nbsp;Aina Cardús ,&nbsp;Marta Pratcorona ,&nbsp;Maria Rozman ,&nbsp;Marta Aymerich ,&nbsp;Neus Villamor ,&nbsp;Dolors Colomer ,&nbsp;Jordi Morata ,&nbsp;Anna Esteve-Codina ,&nbsp;Sílvia Beà ,&nbsp;Jordi Esteve ∗","doi":"10.1016/j.bneo.2025.100068","DOIUrl":"10.1016/j.bneo.2025.100068","url":null,"abstract":"<div><h3>Abstract</h3><div>In the last few years, whole-transcriptome sequencing has shown a high number of low-frequency fusion transcripts (FTs) involved in acute myeloid leukemia (AML) pathogenesis. Most of them are not identifiable through conventional diagnostic techniques. In this research, using RNA sequencing, we have investigated FTs in 109 cases of AML without recurrent genetic abnormalities (as defined by the fourth edition of the World Health Organization Classification of Hematolymphoid Tumours). We identified and validated 6 well-known AML-causing FTs (Tier-1), 9 FTs in which recurrently affected genes in AML were involved (Tier-2), and 4 Tier-3 FTs, along with other FTs found in healthy tissue databases (Tier-4). We highlighted 2 previously unknown FTs (<em>ARHGAP11A</em>::<em>NUTM1</em> and <em>RAP1B</em>::<em>GPC3</em>) that constitute putative driver fusion genes in AML after performing a thorough analysis of their intrinsic properties, expression pattern, and clinical data correlation. Altogether, 15 patients from our cohort (14%) presented at least 1 validated FT, half of which had diagnostic and/or therapeutic implications. Furthermore, we were able to monitor 8 FTs during disease evolution, finding a good correlation with tumor burden. Nevertheless, the significance of many FTs remains unknown, which makes it necessary to enlarge curated FT databases to implement whole-transcriptome sequencing in clinical practice.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"2 2","pages":"Article 100068"},"PeriodicalIF":0.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New leads to enhance tagraxofusp efficacy in pDC-AML","authors":"Morgane Boichut ∗ ,&nbsp;Margaux Poussard ∗ ,&nbsp;Xavier Roussel ,&nbsp;Imane Belakri ,&nbsp;Sabeha Biichlé ,&nbsp;Maxime Fredon ,&nbsp;Florian Renosi ,&nbsp;Romain Boidot ,&nbsp;Olivier Adotevi ,&nbsp;Christopher Brooks ,&nbsp;Francine Garnache-Ottou ,&nbsp;Fanny Angelot Delettre","doi":"10.1016/j.bneo.2025.100066","DOIUrl":"10.1016/j.bneo.2025.100066","url":null,"abstract":"","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"2 2","pages":"Article 100066"},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm","authors":"Zhuoer Xie ,&nbsp;Najla Al Ali ,&nbsp;Ling Zhang ,&nbsp;Peter Papenhausen ,&nbsp;Virginia Olivia Volpe ,&nbsp;Onyee Chan ,&nbsp;Andrew Kuykendall ,&nbsp;Seongseok Yun ,&nbsp;Alison Walker ,&nbsp;Kendra Sweet ,&nbsp;Jeffrey E. Lancet ,&nbsp;Eric Padron ,&nbsp;David A. Sallman ∗ ,&nbsp;Rami S. Komrokji ∗","doi":"10.1016/j.bneo.2024.100062","DOIUrl":"10.1016/j.bneo.2024.100062","url":null,"abstract":"<div><h3>Abstract</h3><div>Most myelodysplastic syndromes/neoplasms (MDS) risk stratification models dichotomize conventional cytogenetic abnormalities into present or absent, neglecting the prognostic impact of clone size (percentage of the total cells/metaphases harboring the chromosome abnormality). We investigated the prognostic value of clone size in 1001 patients with MDS using G-banding and fluorescence in situ hybridization. Clone size correlated with anemia severity and thrombocytosis in del(5q) cases, and with anemia and blast percentage in complex karyotypes. <em>TP53</em> mutation prevalence was significantly elevated in patients with clone size of ≥25% compared with those with &lt;25% (34.2% vs 3%; <em>P</em> = .07). Complex karyotypes with clone size of ≥75% demonstrated superior response to hypomethylating agents (20.8% vs 10%; <em>P</em> = .03). Crucially, clone size of ≥25% independently predicted overall survival and leukemia-free survival, regardless of revised International Prognostic Scoring System (IPSS) or molecular IPSS. Our findings establish clone size as a robust prognostic factor in MDS, warranting its integration into clinical practice and potential incorporation into risk stratification models.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"2 2","pages":"Article 100062"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells","authors":"Anne P. de Groot ,&nbsp;Chelsea R. Wilson ,&nbsp;Ellen Weersing ,&nbsp;Jacobine S. Pouw ,&nbsp;Albertina Dethmers-Ausema ,&nbsp;Huong Nguyen ,&nbsp;Evan F. W. Chen ,&nbsp;Alok Shaurya ,&nbsp;Linda Smit ,&nbsp;Fraser Hof ,&nbsp;Gerald de Haan","doi":"10.1016/j.bneo.2024.100052","DOIUrl":"10.1016/j.bneo.2024.100052","url":null,"abstract":"<div><h3>Abstract</h3><div>Self-renewal of leukemic cells results in the accumulation of dysfunctional blood cells and suppression of normal hematopoiesis. The polycomb group protein chromobox 7 (CBX7) is an epigenetic regulator that represses genes required for differentiation and cell cycle arrest and thereby promotes self-renewal. Because leukemic cells are highly self-renewing, we tested whether pharmacological targeting of CBX7 would reduce self-renewal and induce differentiation of human leukemic cells. We found that existing and newly developed CBX7 inhibitors derepress the epigenome, resulting in reduced ubiquitination of histone 2A and reduced binding of CBX7 to its target genes. This led to reduced cell growth, increased differentiation of leukemic cells in vitro, and delayed engraftment of primary leukemic cells in xenotransplant models. Therefore, pharmacological targeting of CBX7 constitutes a novel therapeutic approach for leukemia.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100052"},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma","authors":"Rudra P. Dutta ,&nbsp;Santiago Thibaud ,&nbsp;Violetta Leshchenko ,&nbsp;Meghana Ram ,&nbsp;David T. Melnekoff ,&nbsp;Sherry Bhalla ,&nbsp;Paula Restrepo ,&nbsp;Vikas A. Gupta ,&nbsp;Benjamin G. Barwick ,&nbsp;Scott Newman ,&nbsp;Jonathan McCafferty ,&nbsp;Feras Hantash ,&nbsp;Ajay K. Nooka ,&nbsp;Hearn J. Cho ,&nbsp;Shambavi Richard ,&nbsp;Cesar Rodriguez ,&nbsp;Adriana Rossi ,&nbsp;Larysa Sanchez ,&nbsp;Ajai Chari ,&nbsp;Lawrence H. Boise ,&nbsp;Alessandro Laganà","doi":"10.1016/j.bneo.2024.100049","DOIUrl":"10.1016/j.bneo.2024.100049","url":null,"abstract":"<div><h3>Abstract</h3><div>Venetoclax, a selective B-cell lymphoma 2 (BCL2) inhibitor, has emerged as a promising therapeutic agent for multiple myeloma (MM), particularly in patients harboring the t(11;14) translocation. In this study, we set out to identify markers of sensitivity and resistance to venetoclax in a real-world patient population, aiming to facilitate the development of personalized therapeutic strategies. Through the analysis of RNA sequencing (RNA-seq) data from relapsed/refractory patients treated with venetoclax, either as a single agent or in combination with other drugs, we unveiled a novel 6-gene signature that significantly stratified patients into risk groups for relapse and further validated its clinical relevance in 2 independent clinical and ex vivo data sets. Our analysis also highlighted the negative impact of chromosome 1q gain, which harbors the myeloid cell leukemia-1 (MCL1) gene, on progression-free survival, even in t(11;14)-positive patients. Encouraged by the well-documented role of MCL1 in resistance to venetoclax in various malignancies and the prognostic importance of the BCL2/MCL1 ratio in our cohort, we explored Cyclin-Dependent Kinase 7 (CDK7) inhibition as a potential strategy to overcome venetoclax resistance. In vitro experiments demonstrated that CRISPR-Cas9–mediated CDK7 depletion led to decreased MCL1 levels, enhancing the sensitivity of MM cells to venetoclax. Moreover, the combination of the CDK7 inhibitor THZ1 with venetoclax markedly induced cell death in venetoclax-resistant MM cells harboring 1q gain, thus offering a rational therapeutic approach, particularly for patients with this aberration. Overall, these findings provide important insights for optimizing venetoclax-based therapeutic strategies in MM.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100049"},"PeriodicalIF":0.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies","authors":"Lawrence A. Stern ∗ ,&nbsp;Vibhuti Vyas ∗ ,&nbsp;Laura Lim ,&nbsp;Christian Huynh ,&nbsp;Ryan Urak ,&nbsp;Ruby Espinosa ,&nbsp;Zhiqiang Wang ,&nbsp;Michalina Silva Thiel ,&nbsp;John C. Williams ,&nbsp;Stephen J. Forman ,&nbsp;Christine E. Brown † ,&nbsp;Xiuli Wang †","doi":"10.1016/j.bneo.2024.100048","DOIUrl":"10.1016/j.bneo.2024.100048","url":null,"abstract":"<div><h3>Abstract</h3><div>In this study, we aim to develop a humanized CD19 chimeric antigen receptor (CAR) that matches the potency of the FMC63 CAR and potentially reduces the risk of immunogenicity. The murine FMC63 single-chain variable fragment (scFv) was humanized yielding 2 lead candidate scFvs, VH4vκ1 and 4D5, which exhibit weaker binding affinity than FMC63 scFv. These humanized CD19-scFvs were incorporated into CAR constructs to generate huCD19R(VH4Vκ1) and huCD19R(4D5) CARs, both containing the 41BB costimulatory domain. The antitumor activity of the CAR T cells was assessed against CD19⁺ and CD19 low-expressing tumors. FMC63 CAR T cells with the same backbone in all studies were used as controls. The results showed that the huCD19R(VH4vκ1) CAR T cells exhibited similar expansion, phenotype, and effector function to the FMC63 CAR upon stimulation with CD19 targets. When the CAR T cells were challenged with CD19-bearing tumors, the huCD19R(VH4vκ1) CAR T cells showed similar proliferation to the FMC63 CAR T cells, whereas the huCD19R(4D5) CAR T cells essentially failed to proliferate. Moreover, the huCD19R(VH4vκ1) CAR T cells exhibited significantly better in vivo antitumor activity than the huCD19R(4D5) CAR T cells when tested against tumors expressing a range of CD19 antigens. Finally, using a hybrid model, we found that the huCD19R(VH4vκ1) T cells had a comparable cytokine secretion profile to that of FMC63 CAR T cells. Furthermore, the huCD19R(VH4vκ1) CAR T cells exhibited efficacy against both CD19⁺ and engineered CD19 low-expressing tumors. These findings suggest that huCD19R(VH4vκ1) CAR T cells may offer enhanced persistence and represent a promising candidate for clinical translation as a therapy for CD19⁺ tumors.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100048"},"PeriodicalIF":0.0,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling","authors":"Hamed Bashiri ,&nbsp;Ahad Khalilnezhad ,&nbsp;Haruhito Totani ,&nbsp;Joe Yeong ,&nbsp;Tae-Hoon Chung ,&nbsp;Felicia Wee ,&nbsp;Yuezhen Xue ,&nbsp;Zhen Wei Neo ,&nbsp;Li Yen Chong ,&nbsp;Wee Joo Chng ,&nbsp;Atsushi Watanabe ,&nbsp;Siok-Bian Ng ,&nbsp;The Phyu ,&nbsp;Toshio Suda","doi":"10.1016/j.bneo.2024.100046","DOIUrl":"10.1016/j.bneo.2024.100046","url":null,"abstract":"<div><h3>Abstract</h3><div>Multiple myeloma (MM) stands as a formidable blood malignancy, necessitating innovative therapeutic approaches. Excessive immunoglobulin production within myeloma cells leads to a buildup of toxic proteins, and autophagy plays a crucial role in their survival by degrading toxic aggregates and generating energy. Membrane-associated RING finger protein 5 (MARCH5) is an E3-ligase positioned at the outer mitochondrial membrane and has been shown to regulate autophagy by competing for MicroRNA 30a (MIR30A). Given the fundamental significance of autophagy in promoting the survival of myeloma cells, coupled with the regulatory role of MARCH5 in autophagic activity, we hypothesized that MARCH5 plays an essential function in MM and holds a pivotal position in the pathogenesis and progression of MM. We identified MARCH5’s unique dependencies in MM cells by analyzing the Cancer Dependency Map, thereby establishing its significance in MM biology. Examining various data sets, including CoMMpass (Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Study) and HOVON (Haemato-Oncology Foundation for Adults in the Netherlands), demonstrated a correlation between MARCH5 expression and patient outcomes. Knockdown of <em>MARCH5</em> revealed a substantial reduction in MM cell viability, which was associated with a decrease in autophagic activity. Mechanistically, we unraveled a novel MARCH5/AKT/FOXO3 axis, wherein MARCH5 regulates autophagy through the Protein Kinase B (AKT)-mediated degradation of Forkhead Box O3 (FOXO3). Compromised MM cell viability observed with <em>MARCH5</em> knockdown was recapitulated in <em>FOXO3</em> knockdown experiments, validating the pivotal role of FOXO3 in mediating MARCH5’s effects. In conclusion, this research highlights the crucial role of MARCH5 in MM, and the identified MARCH5/AKT/FOXO3 axis enhances our understanding of MM biology and provides a foundation for developing targeted therapies.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100046"},"PeriodicalIF":0.0,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy","authors":"Joshua W. D. Tobin ,&nbsp;Venkata A. Chikatamarla ,&nbsp;Marko Matic ,&nbsp;Alison Griffin ,&nbsp;Rakin Chowdhury ,&nbsp;Ross Salvaris ,&nbsp;Amanda Goh ,&nbsp;Harrison Black ,&nbsp;Tsz Hung Tong ,&nbsp;Callum Birks ,&nbsp;Sanjiv Jain ,&nbsp;Elizabeth Goodall ,&nbsp;Shreerang Sirdesai ,&nbsp;Thomas Trevis ,&nbsp;Elizabeth Steinepreis ,&nbsp;Yiyang Chen ,&nbsp;Li Li ,&nbsp;Glenn Broadby ,&nbsp;Naadir Gutta ,&nbsp;Kirk Morris ,&nbsp;Greg Hapgood","doi":"10.1016/j.bneo.2024.100044","DOIUrl":"10.1016/j.bneo.2024.100044","url":null,"abstract":"<div><h3>Abstract</h3><div>Progression of follicular lymphoma (FL) or transformation (TFL) within 24 months of immunochemotherapy (ICT) represent high-risk defining events (HRDE) with poor overall survival (OS). We examined baseline clinical characteristics, imaging, and outcomes for patients experiencing HRDE with newly diagnosed FL requiring ICT. HRDE groups were: relapse or progression of FL within 24 months (FL24), early TFL (transformation &lt;24 months of ICT), late TFL (transformation &gt;24 months of ICT).433 patients were categorized as reference FL (Ref FL), n = 352 (no HRDE); FL24, n = 43; early TFL, n = 29; late TFL, n = 9. Chemotherapy included bendamustine (63%), CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) (27%), or CVP (cyclophosphamide, vincristine, prednisone) (10%); 85% received rituximab/15% obinutuzumab and 48% received maintenance therapy. Compared with Ref FL group, OS from HRDE was inferior for FL24 (hazard ratio [HR], 3.93; 95% confidence interval [CI], 2.14-7.23), early TFL (HR, 8.16; 95% CI, 4.38-15.2), and late TFL (HR, 8.23; 95% CI, 3.18-21.25). OS from HRDE was inferior for early TFL compared with FL24 (HR, 2.08; 95% CI, 1.02-4.21). In multivariable analysis, performance status, lactate dehydrogenase, beta-2-microglobulin and grade 3A were associated with early TFL. Clinical characteristics did not differentiate early TFL from FL24. Maximum standardized uptake value was higher in early TFL but not FL24 compared to Ref FL. Early TFL and FL24 represent different HRDEs and are associated with inferior OS. Distinguishing early TFL from FL24 is important for biomarker development, management and to develop and interpret trials in this area of unmet need.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100044"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142652453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma","authors":"Amrita Y. Krishnan ,&nbsp;Krina K. Patel ,&nbsp;Meera Mohan ,&nbsp;Sundar Jagannath ,&nbsp;Ruben Niesvizky ,&nbsp;Rebecca W. Silbermann ,&nbsp;Ziji Yu ,&nbsp;Tao Long ,&nbsp;Scott R. P. McDonnell ,&nbsp;Deborah Berg ,&nbsp;Keith E. Stockerl-Goldstein","doi":"10.1016/j.bneo.2024.100043","DOIUrl":"10.1016/j.bneo.2024.100043","url":null,"abstract":"<div><h3>Abstract</h3><div>This phase 1b trial aimed to determine the safety, tolerability, and preliminary efficacy of mezagitamab, a subcutaneously administered anti-CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Eligible patients had received ≥3 prior lines of treatment, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and a steroid, or ≥2 prior lines in which 1 included a PI + IMiD, and were refractory or intolerant to ≥1 IMiD and ≥1 PI. Fifty patients were enrolled: 44 received mezagitamab monotherapy (dose-escalating cohorts at 45-1200 mg) and 6 received mezagitamab 300 mg in combination with pomalidomide plus dexamethasone. Patients received mezagitamab weekly for 8 doses, every other week for 8 doses, and monthly thereafter. No dose-limiting toxicities were reported with single-agent mezagitamab, and the recommended phase 2 dose was determined as 600 mg. The most common drug-related treatment-emergent adverse events (TEAEs) were fatigue in the monotherapy cohort (9/44 patients) and neutropenia in the combination cohort (4/6 patients); neutropenia was the only drug-related grade ≥3 TEAE to occur in &gt;1 patient. No infusion reactions occurred, and 4 injection-site reactions were reported. Three patients discontinued treatment due to TEAEs. Among the 22 patients receiving 600 mg mezagitamab, the overall response rate was 47%, and the median duration of response was 22.1 months. Mezagitamab outcomes were comparable to those reported with other anti-CD38 therapies in patients with advanced RRMM. Further development of mezagitamab in myeloma is not planned, but studies are underway in autoimmune conditions. This trial was registered at <span><span>www.ClinicalTrials.gov</span><svg><path></path></svg></span> as #NCT03439280.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100043"},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142652452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma","authors":"Eunice Lai ∗ ,&nbsp;Yu Yang Soon ∗ ,&nbsp;Ainsley Ryan Yan Bin Lee ,&nbsp;Shi Yin Wong ,&nbsp;Cinnie Yentia Soekojo ,&nbsp;Melissa Ooi ,&nbsp;Wee Joo Chng ,&nbsp;Sanjay de Mel","doi":"10.1016/j.bneo.2024.100042","DOIUrl":"10.1016/j.bneo.2024.100042","url":null,"abstract":"<div><h3>Abstract</h3><div>Lenalidomide, ixazomib, and daratumumab have been proposed as maintenance therapies for patients with newly diagnosed multiple myeloma (MM; NDMM). There are, however, no randomized controlled trials (RCTs) comparing them. We conducted a network meta-analysis (NMA) of RCTs comparing these agents against placebo in NDMM. A Bayesian NMA model was used to assess the relative effects of competing treatments on progression-free survival (PFS) and overall survival (OS) in 9 studies including 4115 patients with transplant-eligible MM (TEMM) and 1689 patients with non–transplant-eligible MM (NTEMM). Lenalidomide and daratumumab but not ixazomib were associated with improved PFS compared with placebo in patients with TEMM (lenalidomide [hazard ratio (HR), 0.46; 95% credible interval (CrI), 0.36-0.56]; daratumumab [HR, 0.49; 95% Crl, 0.32-0.76]; and ixazomib [HR, 0.72; 95% CrI, 0.46-1.12]) and those with NTEMM (lenalidomide [HR, 0.46; 95% CrI, 0.29-0.75] and ixazomib [HR, 0.69; 95% CrI, 0.43-1.18]). The PFS benefit for daratumumab was present regardless of whether daratumumab-based induction therapy was received. None of the agents showed an OS benefit, and PFS benefits were not seen in patients with high-risk cytogenetics. Lenalidomide was associated with second malignancies, ixazomib with thrombocytopenia, and daratumumab with pneumonia. We propose that lenalidomide remains the maintenance therapy of choice for NDMM.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142573253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}